IP Library Granted Patent US 10,900,020
Granted Patent B2
US 10,900,020 · App. 15/869,613 · Granted Jan 26, 2021

Methods for culturing minimally-passaged fibroblasts and uses thereof

Inventors: John Maslowski (Pottstown, PA); Myrna F. Thomas (Hainesport, NJ); Marie A. Lindner (Radnor, PA)
Assignee: Fibrocell Technologies, Inc.
C12N5/0656C12N2509/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,900,020
App. No.
15/869,613
Granted
Jan 26, 2021
Kind
B2
Abstract

The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.

Claims (16)

1. A method of preparing a composition comprising a cell-free fibroblast conditioned medium comprising the steps of:

obtaining a small tissue biopsy specimen from a human;

digesting the biopsy specimen with a dissociative or digestive enzyme to form a fibroblast cell suspension, wherein the biopsy specimen is no more than 5 mm in thickness and not more than 12 cm 2 in area;

seeding the fibroblast cell suspension into a first tissue culture flask;

culturing the fibroblast cell suspension in the first tissue culture flask through at most three passages into a sequentially larger tissue culture flask;

harvesting the fibroblast conditioned medium from the cell suspension during the culturing step, wherein the fibroblast cell suspension comprises at least 3×10 8 cells at harvest; and

formulating the conditioned medium into the composition.

2. The method of claim 1 , the method further comprising administering a composition to the human.

3. The method of claim 2 , wherein the composition is administered topically.

4. The method of claim 2 , wherein the composition is injected into a defect in skin, bone, or other connective tissue of the human or an area subadjacent to the defect.

5. The method of claim 4 , wherein the defect is selected from the group consisting of rhytids, stretch marks, depressed scars, cutaneous depressions of non-traumatic origin, scarring from acne vulgaris, hypoplasia of the lip, vocal cord defects, defects of the oral mucosa, the gingival mucosa, or the palatal mucosa or skin, burns, and burn scars.

6. The method of claim 1 , wherein the enzyme is a collagenase.

7. The method of claim 6 , wherein the collagenase is liberase.

8. The method of claim 1 , wherein the enzyme is trypsin.

9. The method of claim 1 , wherein the first tissue culture flask is a T-125 flask, T-175 flask, or T-225 flask.

10. The method of claim 1 , wherein the sequentially larger tissue culture flask is a T-500 flask or multi-layer culture stack.

Assignments (8)
SECURITY INTEREST Recorded Mar 31, 2025
From: CASTLE CREEK BIOSCIENCES, LLC
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070680/0695 →
SECURITY INTEREST Recorded Feb 25, 2025
From: CASTLE CREEK BIOSCIENCES, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 070317/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL TECHNOLOGIES, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 055641/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL SCIENCE, INC.
To: CASTLE CREEK BIOSCIENCES, LLC
Reel/Frame 055642/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2018
From: LINDNER, MARIE A.; THOMAS, MYRNA F.
To: ISOLAGEN, INC.
Reel/Frame 048298/0372 →
CHANGE OF NAME Recorded Aug 29, 2018
From: ISOLAGEN, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 046744/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: MASLOWSKI, JOHN
To: FIBROCELL SCIENCE, INC.
Reel/Frame 046744/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2018
From: FIBROCELL SCIENCE, INC.
To: FIBROCELL TECHNOLOGIES, INC.
Reel/Frame 046744/0210 →
Continuity (4)
Continuation 14280957 · May 19, 2014
Continuation 12438932
Provisional Application 60823871 · Aug 29, 2006
Related Publication 20180346878A1 · Dec 6, 2018